Ann: Appendix 4C - quarterly, page-34

They explained the licensing delay in the last 4C:

"Exclusivity and Licensing Agreements: The Company has been engaged in exclusivity and licensing discussions with multiple players across two specific technologies, Alexiflam SYNTM and AlexiflamTM NF. Given the value of these license opportunities, Alexium has conducted a process of engaging with multibillion-dollar global chemical companies within specific markets. The Company had been expecting to close a license deal in the December quarter but with the need to balance the returns from marketing these products itself versus significant passive license income and the number of engaged companies, the Company is taking additional time to achieve the best value exclusivity agreements for both the NF and SYN products with a global chemical manufacturer and supplier."